NCM
ABVX

Nantahala Capital Management’s Abivax ABVX Stock Holding History

Nantahala Capital Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.3M Sell
137,237
-15,998
-10% -$1.89M 0.56% 47
2025
Q4 		$20.7M Sell
153,235
-404,329
-73% -$44.1M 0.68% 31
2025
Q3 		$47.3M Sell
557,564
-925,430
-62% -$56.7M 1.64% 12
2025
Q2 		$11.3M Hold
1,482,994
– – 0.44% 48
2025
Q1 		$9.27M Buy
1,482,994
+46,947
+3% +$318K 0.37% 43
2024
Q4 		$10.5M Buy
1,436,047
+450,413
+46% +$4.15M 0.45% 44
2024
Q3 		$11.4M Hold
985,634
– – 0.57% 34
2024
Q2 		$13M Sell
985,634
-24,400
-2% -$349K 0.76% 23
2024
Q1 		$14.4M Hold
1,010,034
– – 0.83% 28
2023
Q4 		$10.8M Buy
+1,010,034
New +$10.3M 0.65% 34

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Nantahala Capital Management's ABVX Position: Q1 2026 in Review

Nantahala Capital Management reduced its Abivax (ABVX) stake by 10% in Q1 2026, selling an estimated $1.89M and leaving 137,237 shares worth $15.3M. The position accounts for 0.56% of the portfolio, ranked #47.

Nantahala Capital Management first reported a position in ABVX in Q4 2023 and has held it in 10 quarters since. The position peaked at $47.3M in Q3 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Nantahala Capital Management held 137,237 shares of Abivax worth $15.3M as of Q1 2026.
  • Nantahala Capital Management sold 15,998 Abivax shares in Q1 2026, an estimated $1.89M.
  • Abivax made up 0.56% of Nantahala Capital Management's portfolio in Q1 2026, its #47 holding.
  • Nantahala Capital Management first reported a position in Abivax in Q4 2023 and has held it in 10 quarters since.
  • Nantahala Capital Management's Abivax position peaked at $47.3M in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.